3 Stocks Pushing The Drugs Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 16 points (-0.1%) at 16,836 as of Monday, June 30, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,605 issues advancing vs. 1,347 declining with 197 unchanged.

The Drugs industry currently sits up 0.4% versus the S&P 500, which is unchanged. A company within the industry that increased today was Regeneron Pharmaceuticals ( REGN), up 2.1%. On the negative front, top decliners within the industry include Allergan ( AGN), down 2.3%, Eli Lilly and ( LLY), down 0.9%, Mylan ( MYL), down 0.9% and Bristol-Myers Squibb Company ( BMY), down 0.7%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Illumina ( ILMN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Illumina is up $7.58 (4.4%) to $180.28 on average volume. Thus far, 1.4 million shares of Illumina exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $172.50-$180.48 after having opened the day at $174.34 as compared to the previous trading day's close of $172.70.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $22.0 billion and is part of the health care sector. Shares are up 56.2% year-to-date as of the close of trading on Friday. Currently there are 9 analysts who rate Illumina a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Illumina Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

IPOs That Should Be on Your Radar

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Trader's Daily Notebook: Anemic Trading Would Be an Improvement